30Oct 2023
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

In a phase 3 trial, combining the KRAS G12C inhibitor sotorasib with panitumumab, an EGFR inhibitor, showed promising results in patients with metastatic colorectal cancer. The study included 160 patients and those receiving sotorasib at 960 mg or 240 mg daily with panitumumab had significantly longer progression-free survival (5.6 and 3.9 months, respectively) compared to standard care (2.2 months). Objective response rates were 26.4%, 5.7%, and 0% in the respective groups. Treatment-related adverse events were manageable, with skin-related issues and hypomagnesemia being common. This combination therapy demonstrates potential for improving outcomes in chemorefractory metastatic colorectal cancer patients.

  • #oncology

Like

Save

Share